Effect of Meibomian Gland Related Therapy on the Morphology of Meibomian Gland

Not Applicable

Withdrawn

• Conditions: Xerophthalmia
• Interventions: Other: Hot compress massage; Device: Intense pulsed light therapy

• Registration Number: NCT04636372
• Lead Sponsor: Yune Zhao

Brief Summary

200 participants at Eye Hospital of Wenzhou Medical University during September, 2020 to November, 2020 will be enrolled in this study. The meibomian gland related therapy are pulsed light therapy and meibomian gland hot compress massage.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-09
• Study Start: 2020-09-01
• Study First Submitted: 2020-09-30
• Study First Submitted QC: 2020-11-12
• Last Update Submitted: 2020-11-12
• Study First Posted: 2020-11-19
• Last Update Posted: 2020-11-19
• Primary Completion: 2021-01-31
• Study Completion: 2021-01-31

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Previously untreated patients with xerophthalmia

Exclusion Criteria

• No history of ocular surgery and trauma
• Any eye diseases except xerophthalmia
• No treated for xerophthalmia before
• Successful completion of follow-ups

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Hot compress massage group	Hot compress massage	-
Intense pulsed light therapy group	Intense pulsed light therapy	-
Intense pulsed light therapy and hot compress massage group	Hot compress massage	-
Intense pulsed light therapy and hot compress massage group	Intense pulsed light therapy	-

Primary Outcome Measures

Name	Time	Method
The length of meibomian glands after the treatment.	up to 2 months	Length in millimeters.
The area of meibomian glands after the treatment.	up to 2 months	Area in millimeters\^2.
The percentage of meibomian glands after the treatment.	up to 2 months	Percentage of meibomian glands in %(area of meibomian glands (mm\^2) and area of palpebral conjunctiva (mm\^2) will be combined to report percentage of meibomian glands in %) are used to assess this outcome measure.